NextFin news, On Wednesday, October 8, 2025, UK government officials confirmed they are in advanced discussions with the US Administration to adjust the National Health Service's (NHS) drug pricing framework. The talks aim to raise the cost-effectiveness threshold used by England's NHS spending watchdog, the National Institute for Health and Care Excellence (NICE), by 25% to make it easier for NHS patients to access more expensive medicines.
This potential change is part of efforts to stave off tariffs threatened by former US President Donald Trump, who has proposed imposing up to 100% tariffs on pharmaceutical imports unless companies begin construction of manufacturing plants in the US. The UK government is seeking to secure the best outcome for the UK by negotiating terms that avoid such tariffs.
NICE currently assesses medicines based on clinical and cost effectiveness using quality-adjusted life years (QALYs), generally considering drugs costing between £20,000 and £30,000 per additional QALY as good value. Raising this threshold would allow the NHS to approve more costly drugs but would increase overall medicine expenditure.
Science Minister Lord Patrick Vallance acknowledged that an increase in NHS medicine prices may be necessary to prevent pharmaceutical investments from leaving the UK. Several major pharmaceutical firms, including GSK and AstraZeneca, have either paused or shelved UK investments this year, citing pricing pressures and a challenging environment compared to countries like the US.
The Trump administration's tariff threats are linked to demands for greater parity in drug pricing and reshoring of pharmaceutical manufacturing to the US. British pharmaceutical companies have responded by investing in US facilities, with GSK building an $800 million plant in Pennsylvania and AstraZeneca unveiling a $50 billion US investment plan through 2030.
A government spokesperson stated, "The pharmaceutical sector and the innovative medicines it produces are critical to our NHS, our economy and the Plan for Change. Through our Life Sciences Sector Plan, we've committed to working with industry to accelerate growth in spending on innovative medicines compared to the previous decade." The spokesperson also highlighted a landmark economic partnership with the US aimed at improving conditions for pharmaceutical companies and exports.
The discussions come amid broader US tariff threats affecting other UK sectors, including automotive and entertainment, complicating the UK-US trade relationship established in May 2025. The UK government is balancing the need to maintain affordable NHS medicines with the imperative to protect trade and investment ties with the US.
Sources: upday News, Politico, PA Media
Explore more exclusive insights at nextfin.ai.
